Companies › Shanghai Auzone Biological Technology
1 active drug program in 2 registered trials: 2 Phase 2; Neurology, Psychiatry; next expected readout Oct 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TTYP01 Tablets | – | Phase 2 | Autism Spectrum Disorder (ASD); AD | Oct 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06757504 | TTYP01 Tablets | Phase 2 | Autism Spectrum Disorder (ASD) | Psychiatry | Feb 2026 |
| NCT07252440 | TTYP01 Tablets | Phase 2 | AD | Neurology | Oct 2028 |
No annotated target.
–
Spinogenix Reunion Neuroscience TrueBinding Noema Pharma MapLight Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.